MedTrace Logo

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

NCT00987337 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2014-01-27

Study results available
· View outcomes & findings →

Summary

The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) compared to peginterferon/ribavirin (pegIFN/RBV) therapy alone.

Conditions

  • Hepatitis
  • Hepatitis C

Interventions

DRUG

Filibuvir

300 mg BID

DRUG

Filibuvir

600 mg BID

DRUG

Placebo

BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Germany
  • Hungary
  • Puerto Rico
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987337 on ClinicalTrials.gov